The process of formation of red blood cells is termed as erythropoiesis. Erythropoiesis takes place in the bone marrow. Agents promoting synthesis of red blood cells are known as erythropoiesis-stimulating agents. These are recombinant versions of a hormone erythropoietin, which is naturally produced by the kidneys and is responsible for stimulating bone marrow for red blood cells synthesis. Erythropoiesis-stimulating agents are recommended for the treatment of anemia. Hemoglobin is a substance in red blood cells, which carries oxygen around the body. When the body does not receive enough oxygen because of less number of red blood cells, it results into anemia. Anemia is highly associated with chronic kidney disease, and the overall prevalence rate of the disease in the U.S. is 15%. About 50% of the population with advanced diseases develop anemia. Hence, besides the use of dialysis, the development and use of erythropoiesis-stimulating agents are significant advancements in treating patients with chronic kidney disease. These agents were introduced in 1980s and became a popular treatment for anemia.
In cases wherein patients cannot undergo blood transfusions, it becomes necessary to give them erythropoiesis-stimulating agents, also known as recombinant erythropoietin. Epoetin alfa (under the brand name Procrit and Epogen) and darbepoetin alfa (under the brand name Aranesp) are two agents approved by the FDA for treating anemia caused due to chemotherapy, chronic kidney disease, and certain treatments for HIV. These agents are given as subcutaneous injections or as intravenous injections. The dose frequency, depending on the patient’s condition, can vary from once in a week or once every two weeks.
Increasing incidence of anemia cases worldwide is driving the growth of the global erythropoiesis-stimulating agents market. In addition, rising awareness about erythropoiesis-stimulating agent therapies is contributing to the market growth. The demand for erythropoiesis-stimulating agents is rapidly increasing due to rising prevalence of chronic kidney disease and cancer and growing demand for cheaper erythropoietin drugs. Efforts are taken by researchers and pharmaceutical companies to develop novel erythropoietin drugs. However, stringent regulatory norms and side effects such as hypersensitivity, hypertension, seizures, or convulsions associated with erythropoiesis-stimulating agents are restraining the market growth.
The global erythropoiesis synthesis market can be broadly divided into two segments, namely biologics and biosimilars. On the basis of product type, the market can be segmented as epoetin-alfa, epoetin-beta, epoetin-zeta, epoetin-omega, epoetin-lambda, epoetin-delta, and darbepoetin-alfa. The latest product marketed as erythropoiesis-stimulating agent is darbepoetin, and the market for this agent is expected to grow during the forecast period. In terms of application, the market is segmented as erythropoietin agents used in treatment of kidney disorders, cancer, anti-retroviral treatment, neural diseases, and anemia caused as a side effect of HIV.
Geographically, the global erythropoiesis-stimulating agents market is distributed over North America, Europe, Asia Pacific, Middle East, Africa, and South America. North America consists of the U.S., Canada, and Mexico. European market for erythropoietin stimulating agents includes countries like U.K., Germany, France, Italy, Spain etc. The erythropoietin stimulating agents market in Asia Pacific includes countries such as China, Japan, India, South Korea, Australia & New Zealand, and rest of Asia Pacific. North America accounted for the largest market value, but Asia Pacific is expected to expand at a high CAGR during the forecast period. The emerging economies and new products with better efficacy will be a big opportunity for the erythropoietin stimulating agents market.
Key players operating in the global market include Biocon, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Biosidus, and Ranbaxy Laboratories Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.